Kornimate/medical-research-clean huggingface dataset:
montage of htdcs in psycho-cognitive functions in fm

Conditions: Fibromyalgia

Summary: this study aims to map the impact of anodic transcranial direct current stimulation (tdcs) for prolonged home use applied to the primary motor cortex and the left dorsolateral prefrontal córtex (dlpfc), compared to the respective treatments simulated in fibromyalgia.

this study aims to map the impact of anodic tdcs for prolonged home use applied to the primary motor cortex and the left dorsolateral prefrontal córtex (dlpfc), compared to the respective treatments simulated in fibromyalgia, targeting the outcomes of the following axes: (1) pain intensity and functional capacity; (2) psycho cognitive functions; (3) neurophysiological markers; (4) biological rhythm markers; (5) to map the potential of neurophysiological markers, biological rhythm and history of trauma in childhood and adolescence in functional capacity, depressive symptoms and working memory tests.

Eligibility criteria:
inclusion criteria: * women aged 30 to 65 years; who can read and write, with a confirmed diagnosis of fm according to the criteria of the american college of rheumatology (2010-2016). pain score equal to or greater than six on the numeric pain scale (nps 0-10) on most days in the last 3 months. exclusion criteria: * living outside porto alegre area and pregnancy. * contraindications to tms and tdcs: metallic implant in the brain; medical devices implanted in the brain, cardiac pacemaker; aneurysmal clip; metallic cochlear prosthesis, ear implants, and non-removable hearing aids; infusion pumps (including implantable); cranial halos. pregnant women, shift work, use of exogenous melatonin, history of alcohol or drug abuse in the last 6 months, neurological pathologies, history of head trauma or neurosurgery, decompensated systemic chronic diseases, chronic inflammatory diseases (lupus, rheumatoid arthritis, reiter's syndrome), personal history of cancer, past or under treatment.

Keywords: fibromyalgia chronic pain tdcs tms bdnf cortical connectivity
durolane versus methylprednisolone in knee osteoarthritis

Conditions: Knee Osteoarthritis

Summary: the primary objective is to determine whether durolane is non-inferior to methylprednisolone, as assessed by level of pain, when each are given as single intra-articular injections for the relief of pain, in the treatment of symptomatic osteoarthritis of the knee at 12 weeks.


Eligibility criteria:
inclusion criteria: * subject (female or male) 35-80 years of age * unilateral knee pain * radiographic evidence of oa * womac pain score of 7-17 * subject normally active * subject has attempted but not responded adequately to previous non-pharmacological therapy(ies); * subject cooperative and able to communicate effectively with the investigators; * body mass index ≤ 40 kg/m2; * signed informed consent obtained. exclusion criteria: * knee effusion * contralateral knee oa * clinically significant joint pain from joints other than the knee * previous intra-articular steroid injection into the study knee within the last 3 months; * previous intra-articular ha injection into the study knee within the last 9 months; * previous allergic type reaction to a ha product, a steroid, or lidocaine/related anesthetics; * treatment with analgesics other than paracetamol (acetaminophen) (including topical agents for the knee) within 5 half lives of the drug prior to the baseline visit; * use of systemic glucocorticosteroids (excluding inhaled steroids) within the last 3 months; * treatment with glucosamine/chondroitin sulfate initiated within the past 3 months * change in physical therapy for the knee within the last three months * arthroscopy or other surgical procedure in the study knee within the past 12 months; * any planned arthroscopy or other surgical procedure during the study period; * previous history or presence of active septic arthritis * active skin disease or infection in the area of the injection site; * systemic active inflammatory condition or infection * bleeding diathesis or use of anticoagulants * current uncontrolled diabetes mellitus; * any medical condition that in the opinion of the investigator makes the subject unsuitable for inclusion * pregnant or breastfeeding woman or woman of childbearing potential not practicing adequate contraception; * involvement in other clinical trials

Keywords: comparative randomized double-blind non-inferior knee oa
intermediate and long term vascular effects of cisplatin in patients with testicular cancer

Conditions: Testicular Cancer; Cardiovascular Diseases; Cardiovascular Risk Factor

Summary: chemotherapy drugs improve cancer survival but increase the risk of cardiovascular disease (cvd). vegf inhibitors (vegfi) cause severe hypertension, while cisplatin appears pro-thrombotic. hence while cancer survival may improve, this is at the risk of potentially severe cvd and associated morbidity. mechanisms underlying the cardiovascular toxicities of vegfi and cisplatin are unknown, but effects on vascular function may be important. the intellect study will phenotype the endothelial effects of vegfi and cisplatin using a variety of methods.

there remains an unmet need to identify a preventive treatment for patients with testicular cancer treated with platinum based chemotherapy to diminish the risk of subsequent cardiovascular events. a future randomised trial of statin therapy in these patients is under consideration and results from this study will inform its design. the information gained from this pilot study will guide the development of interventional pharmacological studies that are directed towards the most appropriate pathophysiological processes, at the most appropriate time and in the most appropriate patient groups treated with platinum based chemotherapy for testicular cancer.

Eligibility criteria:
inclusion criteria: * histological diagnosis of stage 1 low-risk germ cell testicular cancer treated with orchidectomy, or igccc good or intermediate prognosis metastatic testicular/retroperitoneal germ cell cancer treated with orchidectomy (and or retroperitoneal surgery) plus cisplatin based chemotherapy, 12 - 18 months or 5 - 7 years previously. * aged between 18 and 50 years inclusive, at time of enrolment exclusion criteria: * unable to provide written, informed consent * unable or unwilling to attend for investigations * current active involvement in a clinical trial * those receiving drug treatment for any vascular disease: o including hypertension, hyperlipidaemia, cerebrovascular disease, ischaemic heart disease or heart failure * asthma * chronic obstructive pulmonary disease * diabetes mellitus * arial fibrillation/flutter * oral anticoagulation therapy * cigarette smoker or tobacco use * recreational drug use * ongoing inflammatory, infective or autoimmune disease * other malignant disease diagnosed in previous 7 years * previous venous or arterial thrombotic/thromboembolic event
comparison of interlock nailing versus dynamic compression plating in transverse fractures of tibia

Conditions: Transverse Fracture of Shaft of Tibia

Summary: study aims to compare two treatment modalities for treatment of transverse fractures of tibia. one is intramedullary interlocking nail and the other is dynamic compression plate.

this study is a comparison of two devices used to teat transverse fractures of tibia and these include intra medullary rod popularly known as intra medullary nail and the second is a weight bearing device know as dynamic compression plate which is fixed with screws to diaphyseal segment of bone.

Eligibility criteria:
inclusion criteria: - patients with closed transverse tibial fractures exclusion criteria: - patients unsuitable for surgical intervention
postpartum oxytocin administration in the era of delayed cord clamping

Conditions: Postpartum Hemorrhage

Summary: increased blood loss after vaginal or cesarean delivery is one of the top causes of maternal complications. oxytocin is a common medication given to mothers by iv or an injection to limit the amount of blood loss after delivery. the investigators do not know the best time after delivery that oxytocin should be given. this research is being done to find out if starting the medication oxytocin right after the baby is born or after the placenta comes out decreases the amount of blood lost after birth when we delay cord clamping after birth.

the optimal timing of prophylactic oxytocin administration on both maternal and neonatal outcomes has not been definitively established with delayed cord clamping. maternal considerations include the risk of postpartum hemorrhage, need for additional uterotonic medications, need for maternal transfusion, retained placenta, and postpartum drop in hemoglobin. neonatal considerations include markers of neonatal well-being such as arterial ph and 5-minute apgar score, as well as hemoglobin and bilirubin levels. there is currently no protocol on the timing of third stage prophylactic oxytocin and its administration is based on physician/ delivery provider's preference. the investigators propose a quality assessment initiative, through a randomized controlled trial designed to compare the blood loss between administrations of prophylactic oxytocin immediately after delivery of the neonate versus after delivery of the placenta with delayed cord clamping.

Eligibility criteria:
inclusion criteria: * all laboring women (induced, augmented, or spontaneous) at term admitted to labor and delivery while comfortable * scheduled cesareans * women aged 18 years or older * admitted at newyork-presbyterian morgan stanley children's hospital (chony) or allen pavilion labor and delivery units exclusion criteria: * multifetal gestation * placental abruption or antepartum hemorrhage * maternal bleeding disorder * known fetal anomaly or anemia * fetal growth restriction with abnormal doppler * significant maternal anemia (pre-operative hemoglobin ≤ 7g/dl * intrapartum stillbirth * placenta accreta spectrum * abnormal placentation (previa or abruption) * planned cord blood banking * refusal of blood products * any contraindication for delayed cord clamping * maternal history of aortic stenosis or pulmonary hypertension or other severe cardiac structural disease
to demonstrate the relative bioequivalence of lisinopril 1 x 40 mg tablets under fasting conditions

Conditions: Hypertension

Summary: to demonstrate the relative bioequivalence of lisinopril 1 x 40 mg tablets under fasting conditions.


Eligibility criteria:
inclusion criteria: * no clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening. exclusion criteria: * positive test results for hiv or hepatitis b or c. * treatment for drug or alcohol dependence.
prognostic value of progesterone for in vitro fertilization (ivf) outcome

Conditions: Subfertility

Summary: this observational study attempts to investigate the potential role of serum progesterone levels on the day of hcg administration (thus, the end of the follicular phase) on the probability of pregnancy, in patients undergoing ivf with the use of gnrh antagonists and recombinant gonadotrophins. there has been evidence, that increased serum levels of progesterone are associated with a decreased probability of pregnancy after ivf. this study will attempt to explore the role of progesterone on the outcome of ivf, by closely monitoring its levels during the late follicular phase.


Eligibility criteria:
inclusion criteria: * age \< 40 years * basal fsh \< 12 iu/l * basal p \< 1.6 ng/ml exclusion criteria: * presence of cystic formations at the ovaries during the basal ultrasound scan (prior the initiation of stimulation) * women with polycystic ovaries syndrome (pcos) * women with stage iii-iv endometriosis * women with a pathological condition of the adrenal glands
comparative effectiveness of a breath-operated albuterol inhaler in asthma patients with poor inhaler technique

Conditions: Asthma

Summary: this study was designed to examine the effectiveness of a breath-operated albuterol inhaler in asthma patients who have difficulty using their standard "press-and-breathe" inhaler.

this was a single-center, randomized, open-label, active-controlled, 2-period, 2-sequence, single dose-dose, crossover comparison of the ability of albuterol boi-hfa to produce bronchodilation relative to that produced by to albuterol mdi-hfa in at least 12 asthmatics with poor inhaler coordinating ability.

Eligibility criteria:
inclusion criteria: * asthma diagnosed ≥6 months prior and stable for 4 weeks prior to screening * poor inhaler coordination as assessed at screening * reversible bronchoconstriction (≥ 12% increase in fev1) exclusion criteria: * albuterol allergy * investigational drug within 30 days * injected corticosteroid within 6 weeks * requires beta-blockers, mao inhibitors, tricyclic antidepressants, long-acting beta-blockers, steroids other than those inhaled * other criterial apply
middle age muscle krill study

Conditions: Sarcopenia

Summary: this study will determine the effect of 6 months of supplementation with krill oil on muscle strength and mass in middle-aged adults. the study hypothesis is that krill oil supplementation will increase muscle strength and mass in middle-aged adults.


Eligibility criteria:
inclusion criteria: * be 35-60 years old * have a bmi of less than 35kg/m2 exclusion criteria: * people with diabetes, severe cardiovascular disease, seizure disorders, uncontrolled hypertension (\>150/90mmhg at baseline measurement), cancer or cancer that has been in remission \<5 years, ambulatory impairments which would limit the ability to perform assessments of muscle function, dementia, on anticoagulant therapy, and/or taking medication known to affect muscle (e.g., steroids). * people who have allergies to seafood, and/or regular consumption of more than 1 portion of oily fish per week. * people who perform regular (\>1 day/week) resistance exercise training.

Keywords: krill oil muscle strength muscle mass middle-aged
the prompt pilot study

Conditions: Tobacco Use Disorder; Tobacco Dependence; Tobacco Use Cessation

Summary: the prompt pilot study is a feasibility mixed methods prospective cohort study following principles of community-based participatory action research. the study recruited 80 people who use drugs and followed them for 6 months while providing access to counselling, nicotine replacement therapy and peer-support in a community setting. a notable reduction in average cigarette use per day (20.5 to 9.3) and illicit substance use (18.8%) was observed at study-end. prompt's patient engagement model is an effective harm-reduction strategy for the growing opioid use crisis and can improve the health outcomes of marginalised at-risk populations worldwide.

objective to determine the feasibility of a community-based participatory tobacco dependence strategy (prompt) in the inner city population of ottawa (canada). design a feasibility mixed methods prospective cohort study following principles of community-based participatory action research. intervention recruited 80 people who use drugs, followed them for 6 months while providing access to counseling, nicotine replacement therapy and peer-support in a community setting. setting community research office in downtown ottawa, adjacent to low-income housing, shelter services and street-based drug consumption. primary outcome retention rate at 6-month follow-up. secondary outcome biochemically validated 7-day point prevalence smoking abstinence at 26 weeks, self-reported abstinence in the past 7 days with exhaled carbon monoxide ≤10 ppm.

Eligibility criteria:
inclusion criteria: * currently living in ottawa for at least 3 months prior to enrolment * 16 years or older * have used drugs in the past year (excluding marijuana and alcohol) * have smoked tobacco in the past 7 days exclusion criteria: * consent declined (refusal from participant or decision maker) * any person accessing addictions treatment (in-patient drug rehabilitation) and hence unavailable for follow-up * any person currently or recently (in the past 30 days) enrolled in a smoking cessation program * anyone with a terminal illness with a life expectancy of \<3 months.
elective induction vs spontaneous labour in patients with heart disease

Conditions: Heart; Disease,Complicating Pregnancy, Pre-existing

Summary: fifty pregnant patients with acquired and congenital heart disease between 38-41 weeks were randomised into elective induction and spontaneous labour groups only after bishop score was equal to or more than 6.it was concluded that induction of labour with oxytocin is a relatively safe procedure in women with low risk heart disease with nyha class i and ii. it resulted in a similar caesarean delivery rate and was not associated with more maternal and neonatal complications.

induction of labour was done with oxytocin. an infusion of 30u oxytocin diluted in 500ml normal saline was prepared and given through infusion pump at initial rate of 3mu/min. subsequently dose was increased 3mu/min every 45 min till adequate uterine contractions were established. epidural analgesia was provided wherever feasible or injection morphine 2-5mg was given intravenously for pain relief.

Eligibility criteria:
inclusion criteria: * nyha class i-ii * cephalic presentation * singleton gestation exclusion criteria: * previous cesarean section, * primary pulmonary hypertension, * eisenmenger syndrome, * marfan syndrome, * left heart obstruction, * prior cardiac event or arrhythmia, * malformed fetus, * severe anemia (\<7g/dl), * intrauterine fetal death, * other obstetrical indications for induction of labour * patients on anticoagulation.

Keywords: induction of labour heart disease patients
sublingual microcirculation in children with compensated t1d using the sdf method

Conditions: Type1diabetes

Summary: the main goal of the study is to describe the sublingual microcirculation of children with type 1 diabetes mellitus (t1d) with stable and satisfactory treatment of the disease and to compare it with previously measured parameters of healthy children, nct05324228.

after recording the basic anthropometric parameters, pressure and pulse, each child who meets the inclusion criteria will have their microcirculation measured using a sidestream dark-field (sdf) probe placed sublingually by one examiner using the sdf method. the measurement will be performed in supine position in a disease-free period, with normal diets, at least 2 hours after the last meal, for girls outside the menses period. premedication or analgesia will not be used. a total of 3 video clips will be recorded from different parts of the sublingual area with a minimum length of 20 seconds in a row, unless the child needs a short break between measurements. the recorded videos will then be processed offline by one evaluator who is trained and experienced in microcirculation evaluation, three best and most stable parts of each video clip will be analysed.

Eligibility criteria:
inclusion criteria: * type 1 diabetes mellitus * informed consent of parents exclusion criteria: * acute infection * period of metabolic decompensation and 14 days after it

Keywords: microcirculation children type1diabetes
hypotension prediction index (hpi) in patients undergoing robotic assisted radical prostatectomy

Conditions: Hypotension During Surgery

Summary: robot assisted radical prostatectomy (rarp) is the leader in robotic treatment for prostate cancer. goal-directed therapy (gdt) is the approach used, but hpi, a machine learning algorithm analysing arterial waveforms, might offer additional benefits. the aim of this prospective randomised study is to evaluate the cumulative amount of intraoperative arterial hypotension episodes in patients undergoing rarp managed by gdt protocol guided or not by hpi algorithm


Eligibility criteria:
inclusion criteria: * all consecutive patients undergoing rarp; american society of anaesthesiology (asa) score i-iii exclusion criteria: * body mass index (bmi) of 18.5 to 35, uncontrolled arrhythmias, myocardial infarction or ischemic/hemorrhagic stroke in the last 6 months, iii/iv stage global initiative for chronic obstructive lung disease, pulmonary fibrosis, contraindication to radial artery cannulation.
development of a clinical and biological database in peritoneal carcinosis (bcb carcinose)

Conditions: Cancer; Peritoneal Carcinosis

Summary: the creation of a prospective clinical-biological base dedicated to peritoneal carcinosis must therefore be able to serve as a support for this essential search for transfer.

the main objective is to improve the knowledge of carcinosis mechanisms to develop a specific treatment. that's why this blood collection and tissue collection is very important for the future, these collection will be permitted to the scientists to develop a research specially for carcinosis.

Eligibility criteria:
inclusion criteria: * patient over the age of 18; * patient managed for peritoneal carcinosis : digestives origins (pancreatic, gastroesophageal junction, colorectal, bowel) or peritoneum cancer * patient eligible for a peritoneal carcinosis treatment : at least one (or more) surgery (s) ;chemotherapy or any treatment for this disease * patient agree will all study procedure : biological samples \& tissues samples * patient giving informed consent exclusion criteria: * patient not affiliated to social protection system * patient unable to understand or comply with study instructions or requirements for psychological, family, social or geographical reasons * the level of french is insufficient to consent to the study and to response to the questionnaires * patient under guardianship * pregnancy ou breast-feeding women * patient treated in case of an emergency
safety and efficacy of nicardipine for the control of blood pressure after sah

Conditions: Subarachnoid Hemorrhage; Intracerebral Hemorrhage

Summary: the purpose of this research is to explore ways to improve and simplify control of blood pressure in patients with sah or ich. this research will be done by comparing tow different medications that are routinely used to help control blood pressure. none of the medications used in this study nor any procedures performed are experimental.


Eligibility criteria:
inclusion criteria: * 18-70 years old (inclusive) * admission to nsicu with a diagnosis of sah or ich exclusion criteria: * patients who are admitted \>48 hours after sah or ich * readmission or second sah * readmission or second ich * large (immediately life threatening) associated intraparenchymal or intraventricular hemorrhage * women who are pregnant

Keywords: patients with sah or ich